Salute e Benessere

CROWN AESTHETICS PROVIDES CAVENDISH CLINICS WITH AWARD-WINNING SKINPEN®…

"We are thrilled to support Cavendish Clinics in bringing the advanced capabilities of SkinPen Precision to their prestigious client base," said Andy Moulton, Vice President of International for Crown Aesthetics. "This offering aligns with our mission to deliver high-quality, innovative solutions for skin rejuvenation and restoration." "We are thrilled to support Cavendish Clinics in bringing the advanced capabilities of SkinPen Precision to their prestigious client…
PR Newswire
06/11/2024

In-depth analysis showing robust Diamyd® treatment effects across clinical…

Summary of the detailed breakdown of the previously published meta-analysis that included data from 627 patients, with a focus on DR3-DQ2 positive patients and high dose (3 or 4 injections) group where available: Summary of the detailed breakdown of the previously published meta-analysis that included data from 627 patients, with a focus on DR3-DQ2 positive patients and high dose (3 or 4 injections) group where available: These results demonstrate the effectiveness of Diamyd ®compared to...
PR Newswire
06/11/2024

Hanmi Unveils Novel Obesity Drug 'HM17321' : A Game-Changer in Overcoming…

SEOUL, South Korea, Nov. 6, 2024 /PRNewswire/ -- Hanmi Pharm. Co., Ltd. has announced promising research results for its novel obesity treatment, HM17321. This groundbreaking drug not only augments fat loss but also significantly increases lean muscle mass, marking it as a potential game-changer in obesity management. HM17321 addresses a key limitation in current GLP-1-based therapies, which often lead to muscle loss as a side effect of significant weight reduction. SEOUL, South Korea , Nov...
PR Newswire
06/11/2024

Groupe Mutuel integrates Ada Health's AI-powered care navigation into their…

Following an assessment, members will receive a recommendation for appropriate care options included in their policy and a referral voucher for reimbursement. Ada assessments are integrated into a member's Groupe Mutuel single sign-on and are available in Italian, French, German, and English. Following an assessment, members will receive a recommendation for appropriate care options included in their policy and a referral voucher for reimbursement. Ada assessments are integrated into a…
PR Newswire
06/11/2024

Invitation to presentation of BioArctic's third quarter report for July -…

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast:https://ir.financialhearings.com/bioarctic-q3-report-2024/register If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID...
PR Newswire
06/11/2024

VALNEVA - Declaration of shares and voting rights: October 31, 2024

VALNEVADeclaration of shares and voting rightsOctober 31, 2024__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: November 6, 2024 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the...
Nasdaq GlobeNewswire
06/11/2024

Ex dividend NOK 0.50 today

The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.50 as from today, 06.11.2024.
Nasdaq GlobeNewswire
06/11/2024

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant…

Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024
Nasdaq GlobeNewswire
06/11/2024

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant…

Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024 Operating profit increased by 21% in Danish kroner and by 22% at constant exchange rates (CER) to DKK 91.6 billion.Sales in North America Operations increased by 31% in Danish kroner (31% at CER). Sales growth in the US was positively...
Nasdaq GlobeNewswire
06/11/2024

IBA signs contract with SteriLab for E-beam sterilization solution in the…

Fourth agreement secured by IBA Industrial Solutions in past six weeksLouvain-la-Neuve, Belgium, November 06, 2024– IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, has been selected by SteriLab to equip its new facility at Haina Port in the Dominican Republic with a cutting-edge Be Soft electron beam (E-beam) sterilization solution. The facility will serve multiple sectors, including medical devices, food products, and semiconductors, helping...
Nasdaq GlobeNewswire
06/11/2024

Press Release: Dupixent approved in the EU as the first and only medicine for…

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing significantly more children aged one to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one yearDupixent is the first-ever medicine in the EU indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth is crucial...
Nasdaq GlobeNewswire
06/11/2024

Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General…

Oslo, November 6, 2024:Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its third quarter 2024 results today. Conference call and webcast scheduled for November 6, 2024, at 14:00 (CET). Link to webcast here .Third Quarter 2024 Business UpdateHighlightsUltimovacs implemented cash preservation initiatives during the second quarter of 2024. During the third quarter of 2024,...
Nasdaq GlobeNewswire
06/11/2024

Research Grid raises $6.5 million to make clinical trials admin-free

With artificial intelligence poised to rapidly accelerate the speed of drug discovery, the funding comes at a critical time for the clinical trials market, which is now seen as the major bottleneck in the drug development process. This is often caused when using legacy software systems and manual processes to manage trials, resulting in inefficiency, errors, and weak patient engagement. Delays to clinical trials are also phenomenally expensive, costing up to $400 million per year, per trial…
PR Newswire
06/11/2024

ROS1 Inhibitors Market Booms as Demand for Targeted Cancer Therapies Escalates |…

Key Takeaways from the ROS1 Inhibitors Market Report Key Takeaways from the ROS1 Inhibitors Market Report Discover which therapies are expected to grab the ROS1 inhibitors market share @ ROS1 Inhibitors Market Report ROS1 Inhibitors Market Dynamics The market dynamics for ROS1 inhibitors are shaped by several key factors, including thegrowing incidence of NSCLC, advancements in precision medicine, and the competitive landscape of pharmaceutical innovation. Theprevalence of...
PR Newswire
05/11/2024

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid…

thAnnual Meeting (SITC), that will take place on November 6-10, 2024 in Houston, Texas.The data will be presented in a poster: Title: Breaking barriers in solid tumors with SMART allogeneic CAR T-cellsDate / Time:November 9 th, 2024 from 9:00am to 8:30pm ET Presenter:Beatriz Aranda-Orgilles, Associate Director, Immuno Oncology at Cellectis Poster number:254Despite the success of CAR T-cell therapies treating blood cancers, these cutting-edge technologies continue to...
Nasdaq GlobeNewswire
05/11/2024

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at…

New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy manufacturing platform delivers fresh, fit cells within a median vein-to-vein time of seven days, with potentially encouraging patient outcomes. Three abstracts, including one oral presentation for GLPG5101 in relapsed/refractory non-Hodgkin lymphoma, and a company showcase, will...
Nasdaq GlobeNewswire
05/11/2024

Lenzing Nonwovens expands its LENZING™ Lyocell Dry fiber portfolio to offer…

The new LENZING™ Lyocell Dry fine fiber can produce nonwoven fabrics with higher density compared to LENZING™ Lyocell Dry standard fiber. With up to 30% more cellulosic fibers in the same space, customers can create strong and soft nonwoven products. These fibers are suitable for use in hygiene applications such as diapers or sanitary pads. The new LENZING™ Lyocell Dry fine fiber can produce nonwoven fabrics with higher density compared to LENZING™ Lyocell Dry standard fiber. With up to 30%...
PR Newswire
05/11/2024

Genmab to Present at Jefferies London Healthcare Conference

Media ReleaseCOPENHAGEN, Denmark; November 5, 2024Genmab A/S (Nasdaq:GMAB) announced today that its Chief Executive Officer , Jan van de Winkel, Ph.D. and Chief Financial Officer , Anthony Pagano will take part in a fireside chat at the Jefferies London Healthcare Conference on November 19 , 2024 at 4:30 PMCET /10:30 AM EST. A webcast of the event will be available on Genmab's website at ...
Nasdaq GlobeNewswire
05/11/2024

At 11.1% CAGR Aesthetic Medical Devices Market Size to Reach $44.60 Billion By…

Read full market research report, "Aesthetic Medical Devices Market Analysis and Forecast by Size, Share, Growth, Trends 2031", published by The Insight Partners. Read full market research report, "Aesthetic Medical Devices Market Analysis and Forecast by Size, Share, Growth, Trends 2031", published by The Insight Partners. Regional analysis - TheAsia Pacific-Aesthetic medical devices market was valued atUS$ 4,158.02 millionin 2023 and is expected to reach...
PR Newswire
05/11/2024

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp…

Media ReleaseCOPENHAGEN, Denmark; November 5, 2024 More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin's lymphoma (NHL) patientsNew and updated data from EPCORE ®clinical trial program reinforce the potential of epcoritamab as a monotherapy and in combination to treat multiple B-cell malignancies across lines of therapy Genmab A/S (Nasdaq:GMAB)announced today more than 20...
Nasdaq GlobeNewswire
05/11/2024

The Rise of Thermostatic Mixers Market: A $5.79 Billion Industry Dominated by…

For Detailed Market Insights, Visit: https://www.theinsightpartners.com/reports/thermostatic-mixers-market For Detailed Market Insights, Visit: https://www.theinsightpartners.com/reports/thermostatic-mixers-market The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the Thermostatic Mixers market comprises a vast array of wall and deck mount which are expected to register strength during the coming years. For More Information...
PR Newswire
05/11/2024

Women's Health Market is expected to generate a revenue of USD 65.23 Billion by…

The global focus on women's health has never been more prominent. With rising investments in healthcare innovations, greater awareness of gender-specific healthcare needs, and the ongoing push toward personalized care, this market is poised for accelerated growth. Verified Market Research®'s new report identifies the challenges, trends, and opportunities critical to industry leaders aiming to harness this growth. The global focus on women's health has never been more prominent. With rising...
PR Newswire
05/11/2024

Roche to present new and encouraging long-term follow-up data across broad…

thAmerican Society of Hematology (ASH) Annual Meeting and Exposition, held 7-10 December 2024 in San Diego, US. The data underscore Roche's commitment to advance patient outcomes in lymphoma with long-term follow-up of its approved medicines Polivy® (polatuzumab vedotin), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab) as well as new investigational combination data.Key presentations include: Five-year data from the phase III POLARIX study (abstract #469) reinforce the potential of...
Nasdaq GlobeNewswire
05/11/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 5 November 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under the...
Nasdaq GlobeNewswire
05/11/2024
Altri  Comunicati